NCT02433704

Brief Summary

To directly compare acute infection rates in patients undergoing total knee replacement with intraosseous regional administration or systemic intravenous administration of prophylactic antibiotics.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started May 2015

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2015

Completed
21 days until next milestone

Study Start

First participant enrolled

May 1, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 5, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

July 28, 2017

Status Verified

November 1, 2015

Enrollment Period

2 years

First QC Date

April 10, 2015

Last Update Submit

July 27, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • rate of acute surgical site infection

    defined as within 3 weeks after the surgical procedure

Secondary Outcomes (4)

  • correlation of clinical comorbidities to acute infection rates

    1 year post surgical intervention

  • number of complications

    1 year post surgical intervention

  • tourniquet time

    during procedure, up to approximately 2.5 hours

  • blood loss

    during procedure, up to approximately 2.5 hours

Study Arms (2)

Intraosseous Administration

ACTIVE COMPARATOR

Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.

Device: New IntraosseousDrug: Cefazolin

Systemic Intravenous Administration

NO INTERVENTION

Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.

Interventions

Intraosseous administration of prophylactic antibiotics

Intraosseous Administration

Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.

Intraosseous Administration

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • primary diagnoses of osteoarthritis

You may not qualify if:

  • history of compartment syndrome
  • allergy to an antibiotic in the study
  • venous stasis
  • peripheral vascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke Medical Plaza Page Road

Durham, North Carolina, 27703, United States

Location

MeSH Terms

Interventions

Cefazolin

Intervention Hierarchy (Ancestors)

Cephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Samuel Wellman, MD

    Duke University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2015

First Posted

May 5, 2015

Study Start

May 1, 2015

Primary Completion

May 1, 2017

Study Completion

June 1, 2018

Last Updated

July 28, 2017

Record last verified: 2015-11

Locations